Kurse werden geladen...
Prognose
Kaufen | 1 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced a publication on GLOPERBA® dosing adjustments in peer-review journal.» Mehr auf globenewswire.com
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL
PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today presented the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.» Mehr auf globenewswire.com
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 4,63 Mio | 54,13% |
Bruttoeinkommen | 3,35 Mio | 39,94% |
Nettoeinkommen | −24,11 Mio | 6,73% |
EBITDA | −25,79 Mio | 21,99% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 37,54 Mio€ |
Anzahl Aktien | 6,95 Mio |
52 Wochen-Hoch/Tief | 70,34€ - 3,15€ |
Dividenden | Nein |
Beta | 1,14 |
KGV (PE Ratio) | −0,96 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | −0,34 |
KUV (PS Ratio) | 0,85 |
Unternehmensprofil
Name | Scilex Holding Co |
CEO | Jaisim Shah |
Mitarbeiter | 115 |
Assets entdecken
Shareholder von Scilex Holding Co investieren auch in folgende Assets